The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1741
November 10, 2025
View Complete Issue         Table of Contents 2019 
Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs
November 10, 2025 (Issue: 1741)
Orlynvah (Iterum Therapeutics), an oral fixed-dose combination of the thiopenem antibacterial prodrug sulopenem etzadroxil and the renal tubular transport inhibitor probenecid, has been approved by the FDA for treatment of uncomplicated urinary...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs
Article code: 1741b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.